Hematology (Dec 2023)

Application of G-CSF in high-leukocyte acute myeloid leukemia is a poor prognostic factor

  • Ping Weng,
  • Shu Yang,
  • Shujuan Xu,
  • Shuxia Zhang,
  • Yong Wu,
  • Yuanzhong Chen

DOI
https://doi.org/10.1080/16078454.2023.2220521
Journal volume & issue
Vol. 28, no. 1

Abstract

Read online

ABSTRACTObjective To analyze the effect of granulocyte colony-stimulating factor (G-CSF) on outcomes in patients with acute myeloid leukemia (AML).Methods A total of 526 patients with AML in the Haematology Department were enrolled. They were divided into a G-CSF treatment group and a no G-CSF group according to whether G-CSF was administered in the induction chemotherapy period, with 355 cases in the G-CSF group and 171 cases in the no G-CSF group. Cox regression analysis and Kaplan-Meier curve analysis were used to analyze the effect of G-CSF on the first complete remission (CR1) phase and overall survival (OS). In addition, further analysis was performed based on an initial white blood cell count of 50 * 10^9/L.Results The application of G-CSF significantly shortened the CR1 phase and OS in patients with high leukocytes.Conclusions G/GM-CSF should be used with caution in patients with AML, especially those with high leukocytes.

Keywords